In the last trading session, 1.09 million AnaptysBio Inc (NASDAQ:ANAB) shares changed hands as the company’s beta touched -0.04. With the company’s per share price at $16.51 changed hands at -$0.22 or -1.31% during last session, the market valuation stood at $506.31M. ANAB’s last price was a discount, traded about -150.21% off its 52-week high of $41.31. The share price had its 52-week low at $12.21, which suggests the last value was 26.04% up since then. When we look at AnaptysBio Inc’s average trading volume, we note the 10-day average is 0.76 million shares, with the 3-month average coming to 945.65K.
Analysts gave the AnaptysBio Inc (ANAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended ANAB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. AnaptysBio Inc’s EPS for the current quarter is expected to be -1.46.
AnaptysBio Inc (NASDAQ:ANAB) trade information
Instantly ANAB was in red as seen at the end of in last trading. With action -1.31%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 24.70%, with the 5-day performance at -1.31% in the red. However, in the 30-day time frame, AnaptysBio Inc (NASDAQ:ANAB) is -14.41% down. Looking at the short shares, we see there were 9.03 million shares sold at short interest cover period of 6.91 days.
The consensus price target for the stock as assigned by Wall Street analysts is 40, meaning bulls need an upside of 58.72% from its current market value. According to analyst projections, ANAB’s forecast low is 19 with 80 as the target high. To hit the forecast high, the stock’s price needs a -384.55% plunge from its current level, while the stock would need to soar -15.08% for it to hit the projected low.
AnaptysBio Inc (ANAB) estimates and forecasts
Year-over-year growth is forecast to reach -54.00% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 13.58M. 11 analysts are of the opinion that AnaptysBio Inc’s revenue for the current quarter will be 8.58M. The company’s revenue for the corresponding quarters a year ago was 7.18M and 10.97M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 89.19%. The estimates for the next quarter sales put growth at -21.81%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -7.30%. The 2025 estimates are for AnaptysBio Inc earnings to decrease by -5.25%, but the outlook for the next 5-year period is at -4.00% per year.
ANAB Dividends
AnaptysBio Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.41% of AnaptysBio Inc shares while 121.92% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 127.54%. There are 121.92% institutions holding the AnaptysBio Inc stock share, with ECOR1 CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 27.4931% of the shares, roughly 7.52 million ANAB shares worth $188.48 million.
FMR LLC holds the second largest percentage of outstanding shares, with 10.4936% or 2.87 million shares worth $71.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund . With 807.47 shares estimated at $13.33 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.18% of the shares, roughly 668.95 shares worth around $11.04 million.
